Literature DB >> 19430332

Advances in the pathogenesis and treatment of polycystic kidney disease.

Vishal Patel1, Renuka Chowdhury, Peter Igarashi.   

Abstract

PURPOSE OF REVIEW: Polycystic kidney disease (PKD) is the most common genetic cause of chronic renal failure. Mouse models of PKD, especially those with mutations in genes that are orthologous to human disease genes, have provided insights into the pathogenesis of cyst formation and advanced the preclinical testing of new drugs. RECENT
FINDINGS: PKD is a ciliopathy that arises from abnormalities in the primary cilium, a sensory organelle present on the surface of most cells. The primary cilium is required for the maintenance of planar cell polarity, which regulates tubular diameter. Acute kidney injury stimulates cell proliferation and promotes cyst formation in a mouse model of PKD. Studies of signaling pathways that are perturbed in PKD have identified new potential therapeutic targets. Drugs that have shown beneficial effects in orthologous animal models of PKD include tolvaptan, octreotide, src inhibitors, CFTR inhibitors, pioglitazone, etanercept, and triptolide.
SUMMARY: Abnormalities in the primary cilium perturb signaling pathways that regulate renal epithelial cell growth and differentiation and lead to the formation of kidney cysts. Acute kidney injury promotes cyst formation and may underlie the variability in disease progression that is observed in affected individuals. Several promising new therapeutic agents that have been validated in orthologous animal models have entered clinical trials in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430332      PMCID: PMC2820272          DOI: 10.1097/MNH.0b013e3283262ab0

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  45 in total

Review 1.  Planar cell polarity and vertebrate organogenesis.

Authors:  Courtney Karner; Keith A Wharton; Thomas J Carroll
Journal:  Semin Cell Dev Biol       Date:  2006-05-26       Impact factor: 7.727

Review 2.  Elucidating the function of primary cilia by conditional gene inactivation.

Authors:  Thomas Hiesberger; Peter Igarashi
Journal:  Curr Opin Nephrol Hypertens       Date:  2005-07       Impact factor: 2.894

3.  Defective planar cell polarity in polycystic kidney disease.

Authors:  Evelyne Fischer; Emilie Legue; Antonia Doyen; Faridabano Nato; Jean-François Nicolas; Vicente Torres; Moshe Yaniv; Marco Pontoglio
Journal:  Nat Genet       Date:  2005-12-11       Impact factor: 38.330

Review 4.  Cilia and centrosomes: a unifying pathogenic concept for cystic kidney disease?

Authors:  Friedhelm Hildebrandt; Edgar Otto
Journal:  Nat Rev Genet       Date:  2005-12       Impact factor: 53.242

5.  Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

Authors:  Xiaofang Wang; Vincent Gattone; Peter C Harris; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

6.  Increased water intake decreases progression of polycystic kidney disease in the PCK rat.

Authors:  Shizuko Nagao; Kazuhiro Nishii; Makoto Katsuyama; Hiroki Kurahashi; Tohru Marunouchi; Hisahide Takahashi; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2006-06-28       Impact factor: 10.121

7.  Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease.

Authors:  Sayu Omori; Mariko Hida; Hisayo Fujita; Hisahide Takahashi; Susumu Tanimura; Michiaki Kohno; Midori Awazu
Journal:  J Am Soc Nephrol       Date:  2006-04-26       Impact factor: 10.121

8.  Disruption of Bardet-Biedl syndrome ciliary proteins perturbs planar cell polarity in vertebrates.

Authors:  Alison J Ross; Helen May-Simera; Erica R Eichers; Masatake Kai; Josephine Hill; Daniel J Jagger; Carmen C Leitch; J Paul Chapple; Peter M Munro; Shannon Fisher; Perciliz L Tan; Helen M Phillips; Michel R Leroux; Deborah J Henderson; Jennifer N Murdoch; Andrew J Copp; Marie-Madeleine Eliot; James R Lupski; David T Kemp; Hélène Dollfus; Masazumi Tada; Nicholas Katsanis; Andrew Forge; Philip L Beales
Journal:  Nat Genet       Date:  2005-09-18       Impact factor: 38.330

9.  The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.

Authors:  Jonathan M Shillingford; Noel S Murcia; Claire H Larson; Seng Hui Low; Ryan Hedgepeth; Nicole Brown; Chris A Flask; Andrew C Novick; David A Goldfarb; Albrecht Kramer-Zucker; Gerd Walz; Klaus B Piontek; Gregory G Germino; Thomas Weimbs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

10.  Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Patricia R Wahl; Andreas L Serra; Michel Le Hir; Klaus D Molle; Michael N Hall; Rudolf P Wüthrich
Journal:  Nephrol Dial Transplant       Date:  2005-10-12       Impact factor: 5.992

View more
  68 in total

1.  MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.

Authors:  M Rafiq Islam; Tamara Jimenez; Christopher Pelham; Marianna Rodova; Sanjeev Puri; Brenda S Magenheimer; Robin L Maser; Christian Widmann; James P Calvet
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  Polycystin-1 regulates STAT activity by a dual mechanism.

Authors:  Jeffrey J Talbot; Jonathan M Shillingford; Shivakumar Vasanth; Nicholas Doerr; Sambuddho Mukherjee; Mike T Kinter; Terry Watnick; Thomas Weimbs
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 3.  Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors:  Gustavo Blanco; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

4.  Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists.

Authors:  Stephanie M Flaig; Vincent H Gattone; Bonnie L Blazer-Yost
Journal:  J Transl Int Med       Date:  2016-09-23

Review 5.  Diagnosis and management of childhood polycystic kidney disease.

Authors:  William E Sweeney; Ellis D Avner
Journal:  Pediatr Nephrol       Date:  2010-10-29       Impact factor: 3.714

Review 6.  Liver and kidney disease in ciliopathies.

Authors:  Meral Gunay-Aygun
Journal:  Am J Med Genet C Semin Med Genet       Date:  2009-11-15       Impact factor: 3.908

7.  Effect of tolvaptan in a patient with autosomal dominant polycystic kidney disease after living donor liver transplantation.

Authors:  Kiyotaka Uchiyama; Kazuya Honda; Ryochi Yoshida; Yuka Kamijo; Mai Yanagi; Mineo Nakatsuka; Yoshitaka Ishibashi
Journal:  CEN Case Rep       Date:  2016-07-27

8.  PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

Authors:  Ronak Lakhia; Matanel Yheskel; Andrea Flaten; Ezekiel B Quittner-Strom; William L Holland; Vishal Patel
Journal:  Am J Physiol Renal Physiol       Date:  2017-09-13

9.  Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy.

Authors:  Edgar A Otto; Toby W Hurd; Rannar Airik; Moumita Chaki; Weibin Zhou; Corinne Stoetzel; Suresh B Patil; Shawn Levy; Amiya K Ghosh; Carlos A Murga-Zamalloa; Jeroen van Reeuwijk; Stef J F Letteboer; Liyun Sang; Rachel H Giles; Qin Liu; Karlien L M Coene; Alejandro Estrada-Cuzcano; Rob W J Collin; Heather M McLaughlin; Susanne Held; Jennifer M Kasanuki; Gokul Ramaswami; Jinny Conte; Irma Lopez; Joseph Washburn; James Macdonald; Jinghua Hu; Yukiko Yamashita; Eamonn R Maher; Lisa M Guay-Woodford; Hartmut P H Neumann; Nicholas Obermüller; Robert K Koenekoop; Carsten Bergmann; Xiaoshu Bei; Richard A Lewis; Nicholas Katsanis; Vanda Lopes; David S Williams; Robert H Lyons; Chi V Dang; Daniela A Brito; Mónica Bettencourt Dias; Xinmin Zhang; James D Cavalcoli; Gudrun Nürnberg; Peter Nürnberg; Eric A Pierce; Peter K Jackson; Corinne Antignac; Sophie Saunier; Ronald Roepman; Helene Dollfus; Hemant Khanna; Friedhelm Hildebrandt
Journal:  Nat Genet       Date:  2010-09-12       Impact factor: 38.330

10.  Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.

Authors:  Bonnie L Blazer-Yost; Julie Haydon; Tracy Eggleston-Gulyas; Jey-Hsin Chen; Xiaofang Wang; Vincent Gattone; Vicente E Torres
Journal:  PPAR Res       Date:  2010-11-01       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.